Document Detail

Label-free MSE proteomic analysis of chronic myeloid leukemia bone marrow plasma: disclosing new insights from therapy resistance.
MedLine Citation:
PMID:  22761178     Owner:  NLM     Status:  MEDLINE    
Chronic myeloid leukemia (CML) is a pluripotent hematopoietic disorder that is currently considered incurable. The tyrosine kinase product of the Philadelphia chromosome, P210 BCR-ABL, provided a pathogenetic explanation for the initiation of the CML chronic phase and is the molecular therapeutic target for the disease. Imatinib mesylate, an orally available BCR-ABL kinase inhibitor, can induce haematologic and cytogenetic remission of CML. However, imatinib resistance occurs frequently, resulting in relapse. New treatment strategies are focusing on resistant CML stem cells and the bone marrow stroma. The identification of novel pathways and mechanisms in the bone marrow microenvironment could significantly contribute to the development of such strategies. In this work, we used a high-resolution label-free MS(E) proteomic approach to identify differential protein expression in the CML bone marrow plasma of responsive and resistant patients. Oxidative lipid metabolism and regulation of the switch from canonical to noncanonical WNT signaling may contribute to CML resistance in the bone marrow compartment.
Luciana Pizzatti; Carolina Panis; Gabriela Lemos; Moisés Rocha; Rubens Cecchini; Gustavo H M F Souza; Eliana Abdelhay
Related Documents :
8370178 - Il-2 receptor gene expression and il-2 production by human preterm newborns' cells.
9177468 - Prevention of superantigen-induced tolerance in vivo by interleukin-2 treatment.
8812688 - Identification of receptors belonging to the ig and c-type lectin superfamilies on nk c...
11369698 - Il-2 linked to a peptide from influenza hemagglutinin enhances t cell activation by aff...
11261818 - Uterine leiomyoma with massive lymphocytic infiltration simulating malignant lymphoma. ...
3871338 - Augmentation of pokeweed mitogen-induced immunoglobulin production by cord t-cell super...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-08-01
Journal Detail:
Title:  Proteomics     Volume:  12     ISSN:  1615-9861     ISO Abbreviation:  Proteomics     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-08-28     Completed Date:  2013-01-08     Revised Date:  2013-02-05    
Medline Journal Info:
Nlm Unique ID:  101092707     Medline TA:  Proteomics     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  2618-31     Citation Subset:  IM    
Copyright Information:
© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Divisão de Laboratórios do CEMO, Instituto Nacional do Câncer, Rio de Janeiro, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / pharmacology*
Bone Marrow / drug effects*,  metabolism,  pathology
Drug Resistance, Neoplasm*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*,  metabolism,  pathology
Lipid Metabolism / drug effects
Lipid Peroxidation / drug effects
Mass Spectrometry / methods
Middle Aged
Piperazines / pharmacology*
Protein Kinase Inhibitors / pharmacology
Protein-Tyrosine Kinases / antagonists & inhibitors
Proteome / metabolism*
Proteomics / methods*
Pyrimidines / pharmacology*
Wnt Signaling Pathway / drug effects
Young Adult
Reg. No./Substance:
0/Antineoplastic Agents; 0/Piperazines; 0/Protein Kinase Inhibitors; 0/Proteome; 0/Pyrimidines; BKJ8M8G5HI/imatinib; EC Kinases
Comment In:
Expert Rev Proteomics. 2012 Dec;9(6):595-8   [PMID:  23256670 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Overcoming hypoxia to improve tissue-engineering approaches to regenerative medicine.
Next Document:  Recording a history of alcohol use in pregnancy: an audit of knowledge, attitudes and practice at a ...